Get the Stockscreener App
1.04
1.89%
-0.02
After Hours:
1.05
0.01
+0.96%
Cognition Therapeutics Inc stock is traded at $1.04, with a volume of 510.78K.
It is down -1.89% in the last 24 hours and up +4.03% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
510.78K
Relative Volume:
0.58
Market Cap:
$91.81M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-1.3165
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-10.34%
1M Performance:
+4.03%
6M Performance:
-60.15%
1Y Performance:
+141.30%
1-Day Range:
$1.03
$1.09
1-Week Range:
$1.02
$1.17
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.04 | 93.57M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
Cognition Therapeutics advancing zervimesine (ct1812) for dementia with Lewy bodies (DLB) psychosis - marketscreener.com
Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes - TradingView
Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis - TradingView
Zervimesine push: Cognition Therapeutics (NASDAQ: CGTX) targets DLB psychosis - Stock Titan
DLB psychosis often untreated — zervimesine study targets hallucinations - Stock Titan
CGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
COGNITION THERAPEUTICS, INC. (CGTX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Can Cognition Therapeutics Inc disrupt its industryQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Cognition Therapeutics Inc. stock a safe buy before earningsWeekly Trend Report & High Conviction Trade Alerts - mfd.ru
Whale Trades: Is Cognition Therapeutics Inc stock heavily shortedPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan
Cognition Therapeutics (CGTX) CEO RSU vesting leads to 5,850-share tax withholding - Stock Titan
Is Cognition Therapeutics Inc. stock overvalued by current metrics2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru
Why Cognition Therapeutics Inc. stock is recommended by analysts2025 Market WrapUp & Reliable Volume Spike Alerts - mfd.ru
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat
Brookline Capital Management Predicts CGTX FY2025 Earnings - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management - Defense World
Cognition Therapeutics extends expanded access program for Zervimesine (CT1812) in dementia with Lewy bodies - marketscreener.com
Cognition Therapeutics rises as it extends access to rare brain disorder drug - TradingView
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6%Still a Buy? - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6% – Still a Buy? - Defense World
Analyst Calls: Is Cognition Therapeutics Inc. stock a safe buy before earnings2025 Top Gainers & Precise Entry and Exit Recommendations - mfd.ru
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug - Investing.com India
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug By Investing.com - Investing.com Canada
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial - TipRanks
Cognition Therapeutics Completes FDA Meeting for Zervimesine in DLB - TradingView
Cognition Therapeutics, Inc. Discusses Phase 2b Study Plans for Zervimesine in Dementia with Lewy Bodies During FDA Type C Meeting - Quiver Quantitative
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Street Watch: What is LCFYWs valuation compared to sectorTrade Risk Assessment & Stock Portfolio Risk Management - baoquankhu1.vn
Gainers Report: Whats next for Cognition Therapeutics Inc stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn
Published on: 2026-01-22 00:29:52 - baoquankhu1.vn
What is the PEG ratio of Cognition Therapeutics Inc.Analyst Downgrade & Capital Efficiency Focused Ideas - bollywoodhelpline.com
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Market Catalysts: What is Cognition Therapeutics Incs debt to equity ratioInsider Selling & Capital Protection Trading Alerts - baoquankhu1.vn
Aug Catalysts: Whats the fair value of Cognition Therapeutics Inc stockPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
Whats the fair value of Cognition Therapeutics Inc stock2025 Price Targets & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
CEO Moves: Is Cognition Therapeutics Inc stock a top pick in earnings season2025 Risk Factors & Precise Trade Entry Recommendations - Bộ Nội Vụ
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Cognition Therapeutics Inc. stock could outperform in 2025Earnings Recap Report & High Yield Equity Trading Tips - Улправда
Trading Recap: Will Cognition Therapeutics Inc. stock outperform growth indexes2025 Analyst Calls & Community Consensus Trade Alerts - ulpravda.ru
How resilient is Cognition Therapeutics Inc. stock in market downturnsJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Weekly Earnings: How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Performance Report & Stepwise Trade Signal Implementation - Улправда
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):